WHWK
Whitehawk Therapeutics, Inc.BS score 52.0MEDIUMPHASE1 · mkt cap $167.5M · rev ttm $7.1M
drug hypothesis
HWK-016 modulates MUCIN-16 (MUC16) to treat Platinum Resistant Ovarian Cancer (PROC).
moa:Antibody-drug conjugate (ADC) that binds to MUC16-expressing tumor cells and delivers a cytotoxic payload (CPT116/CPT119) to kill cancer cells
score breakdown
trial design70
base rate disconnect20
language red flags80
composite52.0
valuation analysis
market cap$167.5M
revenue ttm$7.1M
phasePHASE1
historical base rate5%
disconnect ratio0.7x
lead trialNCT07470853
meta
cik0001422142
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, non-randomized, single-arm study in patients with advanced solid tumors including PROC and endometrial cancer. 21-day cycles. Enrollment of 265 patients. No placebo control.
primary endpoint:Determine Maximum Tolerated Dose (MTD)
claimed differentiation
No differentiation claims provided in available filing data
language red flags
- Insufficient SEC filing business section text provided - only clinical trial data available
- No differentiation claims visible to assess
- Cannot verify stated risks without full SEC filing text
- Trial dates appear to be in the future relative to typical filing dates - verify accuracy of dates provided
company-stated risks
- No explicit risk disclosures in available filing text
upcoming catalysts
- 2026-03-15Trial start
- 2028-02Primary completion (MTD determination)